Factors associated with sclerostin levels – A calcification inhibitor – In individuals with type 2 diabetes mellitus; Is autonomic neuropathy the missing link?

Ioanna Eleftheriadou; Anastasios Tentolouris; Ioanna A. Anastasiou; Iordanis Mourouzis; Dimitrios Tsilingiris; Ourania Kosta; Pinelopi Grigoropoulou; Nikolaos Tentolouris

doi:https://doi.org/10.1016/j.jdiacomp.2020.107677

doi.org/10.1016/j.jdiacomp.2020.107677

Factors associated with sclerostin levels – A calcification inhibitor – In individuals with type 2 diabetes mellitus; Is autonomic neuropathy the missing link?

Ioanna Eleftheriadou

16

,

Anastasios Tentolouris

12

,

..., Nikolaos Tentolouris

22

Journal of Diabetes and its Complications3.00

Volume: 34, Issue: 10, Pages: 107677 - 107677

Published: Oct 1, 2020

Abstract

Sclerostin inhibits bone formation and its expression is upregulated in the vasculature during the arterial calcification process as a counterregulatory mechanism preventing further calcification. Lower extremity arterial calcification (LEAC) is common in neuropathic patients with type 2 diabetes (T2DM). Herein, we investigated for associations between plasma sclerostin levels and diabetic neuropathy as well as LEAC in subjects with T2DM. A...